{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:59:38Z","timestamp":1760057978691,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AYUMI Pharmaceutical Corporation","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: This study aimed to investigate the effectiveness of etanercept biosimilar 1 under real-world clinical conditions in patients with rheumatoid arthritis (RA), using not only clinical evaluation but also musculoskeletal ultrasound (MSUS). Methods: This multicenter, interventional, open-label, single-arm clinical trial conducted a 24-week follow-up. Patients with RA with moderate to high disease activity received weekly subcutaneous injections of etanercept biosimilar 1 at 50 mg\/dose for 24 weeks. The effectiveness was evaluated with clinical indices and MSUS. Results: Twenty-three patients were evaluated during the study period. The primary endpoint involves a change in the Global OMERACT-EULAR Synovitis Score by MSUS in bilateral second\u2013fifth metacarpophalangeal joints from baseline, demonstrating median (IQR) values of 0 (\u22124, 1), including 4 (1, 9.8) and 2 (0, 5) at baseline and 24 weeks, respectively. The clinical endpoints exhibited a good treatment response, with 15 (68%) and 18 (86%) patients achieving low disease activity or remission at 12 weeks and 24 weeks, respectively. Additionally, MSUS scores improved at both 12 and 24 weeks compared to baseline. The patients who achieved power doppler remission (total power doppler score = 0) at 24 weeks demonstrated a shorter disease duration and no previous use of biological disease-modifying antirheumatic drugs compared to those with no power doppler remission. Conclusions: Etanercept biosimilar 1 exhibited significant improvements not only in clinical indices but also in MSUS assessment, indicating its effectiveness at the structural level.<\/jats:p>","DOI":"10.3390\/jcm14051775","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:02:13Z","timestamp":1741240933000},"page":"1775","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Etanercept Biosimilar Initiating for Etanercept-Naive Patients, Using Ultrasound, Clinical, and Biomarker Assessments in Outcomes of Real-World Therapy (ENPORT-NGSK Study): An Interventional, Multicenter, Open-Label, Single-Arm Clinical Trial"],"prefix":"10.3390","volume":"14","author":[{"given":"Remi","family":"Sumiyoshi","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan"},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-995X","authenticated-orcid":false,"given":"Shin-ya","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan"},{"name":"Center for Collaborative Medical Education and Development, Nagasaki University Institute of Biomedical Sciences, Nagasaki 852-8523, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan"},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurika","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Center, Sasebo Chuo Hospital, Sasebo 857-1195, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki 852-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamami","family":"Yoshitama","sequence":"additional","affiliation":[{"name":"Yoshitama Clinic for Rheumatic Diseases, Kagoshima 899-5117, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-831X","authenticated-orcid":false,"given":"Yoshifumi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Saga University Hospital, Saga 849-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-2277","authenticated-orcid":false,"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/annrheumdis-2017-212172","article-title":"Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate","volume":"77","author":"Matsuno","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/annrheumdis-2015-207709","article-title":"Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results from the APPRAISE study","volume":"75","author":"Wakefield","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e000237","DOI":"10.1136\/rmdopen-2015-000237","article-title":"Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study","volume":"2","author":"Boers","year":"2016","journal-title":"RMD Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40744-019-00169-4","article-title":"Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naive or Switching Patients: A Systematic Review","volume":"6","author":"Ebbers","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.23682","article-title":"Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis","volume":"58","author":"Naredo","year":"2008","journal-title":"Arthritis Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/annrheumdis-2012-203158","article-title":"EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis","volume":"72","author":"Colebatch","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.diii.2014.07.006","article-title":"Role of ultrasound in assessing remission in rheumatoid arthritis","volume":"96","author":"Miladi","year":"2015","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1093\/rheumatology\/keu217","article-title":"Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: A systematic review and meta-analysis","volume":"53","author":"Nguyen","year":"2014","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/rheumatology\/ket405","article-title":"Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: Power Doppler subclinical synovitis is associated with bone erosion","volume":"53","author":"Kawashiri","year":"2014","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2007.078451","article-title":"Settings and artefacts relevant in colour\/power Doppler ultrasound in rheumatology","volume":"67","author":"Terslev","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e15118","DOI":"10.1111\/1756-185X.15118","article-title":"The impact of glucocorticoid use on the outcomes of rheumatoid arthritis in a multicenter ultrasound cohort study","volume":"27","author":"Nonaka","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e000427","DOI":"10.1136\/rmdopen-2016-000427","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: A EULAR-OMERACT ultrasound taskforce-Part 2: Reliability and application to multiple joints of a standardised consensus-based scoring system","volume":"3","author":"Terslev","year":"2017","journal-title":"RMD Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/acr.23551","article-title":"Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis from a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan","volume":"70","author":"Nishino","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13075-021-02426-w","article-title":"Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission","volume":"23","author":"Terslev","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/annrheumdis-2019-216169","article-title":"Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial","volume":"79","author":"Tanaka","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","article-title":"The process defines the product: What really matters in biosimilar design and production?","volume":"56","author":"Vulto","year":"2017","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.biologicals.2019.10.009","article-title":"Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis\u2014A comparison in a real-world national cohort","volume":"62","author":"Codreanu","year":"2019","journal-title":"Biologicals"},{"key":"ref_27","first-page":"109","article-title":"Effectiveness and safety of original and biosimilar etanercept (Enbrel(R) vs. Benepali(R)) in bDMARD-naive patients in a real-world cohort of Portugal","volume":"1","author":"Pinto","year":"2022","journal-title":"ARP Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1093\/rheumatology\/kead127","article-title":"Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: Results from the BSRBR-RA","volume":"62","author":"Rokad","year":"2023","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/ard.60.7.660","article-title":"Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis","volume":"60","author":"Barrera","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/apa.13319","article-title":"Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis","volume":"105","author":"Kahn","year":"2016","journal-title":"Acta Paediatr."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1775\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:48:18Z","timestamp":1760028498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051775"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051775","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}